What enzyme do DPP-4 inhibitors block, and what is the direct consequence?
Choose an answer, then check it.
Clinical Pharmacology · Diabetes Medications
DPP-4 Inhibitors
On this page 6 sections
In 30 seconds
DPP-4 inhibitors — sitagliptin, saxagliptin, linagliptin, and alogliptin, the "gliptins" — are oral type 2 diabetes drugs that block the enzyme dipeptidyl peptidase-4, which normally destroys the body's own incretin hormones within minutes of release. Protecting endogenous GLP-1 and GIP gives modest, glucose-dependent lowering with weight neutrality and low hypoglycemia risk alone. They're valued less for potency than tolerability, making them common in older adults or anyone who wants a simple pill over an injectable.
The college version
Mechanism: Protecting the Body's Own Incretins
After a meal, the gut releases incretin hormones — GLP-1 and GIP — prompting insulin release proportional to the glucose load and suppressing inappropriate glucagon. The enzyme dipeptidyl peptidase-4 (DPP-4) normally degrades these hormones within minutes. DPP-4 inhibitors block this enzyme, extending the life of the patient's own GLP-1 and GIP, sustaining glucose-dependent insulin secretion and glucagon suppression around meals.
A Milder Effect Than GLP-1 Agonists
GLP-1 receptor agonists deliver a receptor-saturating dose of incretin mimicry directly, driving substantial glucose lowering and real weight loss, but usually require injection and cause more GI effects. DPP-4 inhibitors work upstream: they only preserve and amplify incretin the body already makes, never exceeding physiologic signaling. The result is weight neutrality rather than weight loss, and more modest glucose lowering — less potency traded for oral dosing and strong tolerability.
Clinical Positioning
Gliptins are typically added when metformin alone is insufficient, or chosen when tolerability outweighs maximal benefit — frail or older adults, those wanting to avoid injections, or patients intolerant of other orals. Because insulin release stays glucose-dependent, hypoglycemia risk alone is low; it rises mainly when combined with insulin or a sulfonylurea, which can independently drive glucose too low.
Cardiovascular and Renal Considerations
Cardiovascular outcome trials found the class generally neutral for atherosclerotic outcomes. However, saxagliptin and alogliptin showed a signal for increased heart failure hospitalization, most relevant with existing heart failure or its risk factors. Most gliptins need dose adjustment as kidney function declines, since they're cleared renally; linagliptin is the exception, eliminated mainly through the hepatobiliary route, making it convenient across renal function without adjustment.
Adverse Effects
Common effects include nasopharyngitis and headache. A distinctive, uncommon reaction is severe, sometimes disabling joint pain arising anytime after starting therapy and resolving on discontinuation. Pancreatitis is an uncommon but recognized concern, so persistent unexplained abdominal pain warrants evaluation and often stopping the drug. Bullous pemphigoid, an autoimmune blistering skin condition, also requires discontinuation if it develops.
A Key Combination Rule
DPP-4 inhibitors and GLP-1 receptor agonists act on the same incretin pathway — one preserving endogenous hormone, the other directly stimulating the receptor — so combining them adds no benefit and is not recommended.
Patient Teaching
Patients should take the medication as prescribed, expect no meaningful weight change, report new or severe joint pain, seek care for persistent abdominal pain or unusual skin blistering, and know hypoglycemia is unlikely unless paired with insulin or a sulfonylurea.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Your body sends "helper messages" every time you eat, telling your pancreas to release the right amount of insulin. Tiny scissors called DPP-4 normally snip up those messages fast. Gliptin pills tape over the scissors so the messages last longer and do more good. It's a gentle nudge, not a shove — no big weight loss, and it rarely crashes blood sugar alone. It's also just a pill, not a shot, which is why some people, especially older folks, prefer it, even though it's not the strongest tool around.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient on a DPP-4 inhibitor alone asks whether she needs to worry about her blood sugar dropping too low. What should she be told, and why?
Show answer
Low hypoglycemia risk when used alone
She can be reassured that gliptins only boost insulin release when blood sugar is already high, so they rarely cause it to drop too low on their own; that risk mainly appears if she's also taking insulin or a sulfonylurea.
A patient calls reporting new, severe joint pain a few weeks after starting a gliptin, with no other clear cause. What should the nurse advise, and why?
Show answer
Stop and report the joint pain
The nurse should advise contacting the prescriber promptly, since severe joint pain is a recognized reaction to this drug class that typically resolves once the medication is stopped.
Quick check
3 questions here. Answers stay hidden until you check.
Compared with GLP-1 receptor agonists, DPP-4 inhibitors typically produce which combination of effects?
Choose an answer, then check it.
Which DPP-4 inhibitor does NOT require dose adjustment for reduced kidney function, due to its route of elimination?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.